BLOG

TB advocates call on Europe to fulfil commitments for new TB vaccines

As representatives of communities affected by tuberculosis (TB) – including survivors, researchers and civil society organizations – we demand long overdue global investments in the research and development of new TB vaccines commensurate with the disease’s devastating impact. The sixth Global Forum on TB Vaccines will be virtually hosted by Toulouse, France this February 22–25…

Read More...

Leveraging COVID-19 public-private partnerships for TB vaccine development

The past few years have created a paradigm shift in the way we globally respond to and address communicable diseases. Though we remain in the midst of the COVID-19 pandemic, several novel vaccine candidates have been developed, manufactured, studied, approved, distributed, and administered to millions of individuals around the world in less than one year….

Read More...

M72/ AS01E Works: Now What?

We recently discussed M72/AS01E and the exciting data suggesting its efficacy in preventing progression of TB disease after people had already been exposed to TB. Today, we will put these findings into context. Some of the excitement regarding this trial stems from the novelty of its findings. Dr. Ann Ginsberg is a TB researcher working…

Read More...

Landmark Trial for Vaccine M72/AS01E

Today, we will look at a landmark trial reporting the full results of a vaccine called M72/AS01E. This trial sought to answer the question: Can this vaccine decrease the rate of TB disease in adults who have already been exposed to TB1? Pulmonary TB, affects the lungs and is the most common form of the…

Read More...

Guest posts published on this blog reflect the views of their authors and persons interviewed and do not necessarily reflect the views of the Stop TB Partnership Working Group on New TB Vaccines.